ID   U-2OSMR
AC   CVCL_A5VB
SY   U-2OS(MR)
DR   Wikidata; Q107117156
RX   PubMed=19638450;
RX   PubMed=25236161;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Mutation; HGNC; 9277; PPM1D; Simple; p.Arg458Ter (c.1372C>T); ClinVar=VCV002445214; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Bone, tibia; UBERON=UBERON_0000979.
DI   NCIt; C9145; Osteosarcoma
DI   ORDO; Orphanet_668; Osteosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0042 ! U2OS
SX   Female
AG   15Y
CA   Cancer cell line
DT   Created: 20-05-21; Last updated: 05-10-23; Version: 5
//
RX   PubMed=19638450; DOI=10.1158/1535-7163.MCT-09-0115;
RA   Duan Z.-F., Choy E., Harmon D., Yang C., Ryu K., Schwab J.H.,
RA   Mankin H.J., Hornicek F.J.;
RT   "Insulin-like growth factor-I receptor tyrosine kinase inhibitor
RT   cyclolignan picropodophyllin inhibits proliferation and induces
RT   apoptosis in multidrug resistant osteosarcoma cell lines.";
RL   Mol. Cancer Ther. 8:2122-2130(2009).
//
RX   PubMed=25236161; DOI=10.1186/1471-2407-14-681;
RA   Duan Z.-F., Zhang J.-M., Ye S.-N., Shen J.K., Choy E., Cote G.M.,
RA   Harmon D., Mankin H.J., Hua Y.-Q., Zhang Y., Gray N.S., Hornicek F.J.;
RT   "A-770041 reverses paclitaxel and doxorubicin resistance in
RT   osteosarcoma cells.";
RL   BMC Cancer 14:681.1-681.11(2014).
//